Upadacitinib may improve self-reported sleep quality at 3 months in patients with rheumatoid arthritis, with sustained benefits seen over the long term.

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

Here are five key takeaways for regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer ...

The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients ...

Today is International Women’s Day. Here is an overview of some of the most significant advances in the treatment of serious ...

Taking GLP-1 RAs is associated with fewer hospitalizations overall and less need for medications used to stop and prevent migraine attacks.

There’s a pay problem in the quest to help those with rare diseases. The uncomfortable truth behind the breakthroughs is that cures only get funded at scale when the economics work. The hidden ...

NexCure, Inc. today launched with a bold mission to address one of healthcare's most pressing challenges: access to advanced, life-saving therapies for patients who need them most. By delivering CAR-T ...

More than 80% of patients with newly diagnosed rheumatoid arthritis, who were using bridging therapy, successfully tapered ...

Twenty percent of potentially eligible youth are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs), with the ...

The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients ...

Adults with chronic migraine using glucagon-like peptide-1 receptor agonists for other conditions are seeking less migraine treatment.